Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment

Leuk Lymphoma. 2008 Feb;49(2):346-9. doi: 10.1080/10428190701799027.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged, 80 and over
  • Chromosome Deletion
  • Chromosomes, Human, Pair 5
  • Female
  • Humans
  • Kidney Diseases / etiology
  • Lenalidomide
  • Middle Aged
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / genetics*
  • Thalidomide / analogs & derivatives*
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • Thalidomide
  • Lenalidomide